Table 4.
Prevalence of individual fibrosis stages in individuals with NAFLD
| Overall results and by diagnostic method | Studies, n | Participants, n | Prevalence (95% CI), % | I2, % |
|---|---|---|---|---|
| F0 | ||||
| Liver biopsy51, 53, 104, 111, 188 | 5 | 1,805 | 74.19 (37.06–93.35) | 99.2 |
| F1 | ||||
| Liver biopsy51, 53, 104, 111, 188 | 5 | 1,805 | 11.02 (3.36–30.66) | 98.4 |
| F2 | ||||
| Liver biopsy51, 53, 104, 111, 188 | 5 | 1,805 | 4.77 (1.71–12.60) | 95.7 |
| F3 | ||||
| Liver biopsy51, 53, 104, 111, 188 | 5 | 1,805 | 2.00 (0.46–8.23) | 95.5 |
| F4 (cirrhosis) | ||||
| Liver biopsy51, 53, 104, 111, 188 | 5 | 1,805 | 0.77 (0.05–11.35) | 98.3 |
NAFLD, nonalcoholic fatty liver disease.